| scholarly article | Q13442814 |
| P50 | author | Joan Carles Domingo Pedrol | Q64854203 |
| Jesús Miguel López Dupla | Q72279378 | ||
| Tomáš Cihlář | Q88483170 | ||
| Francesc Villarroya | Q41464646 | ||
| Marta Giralt | Q41652914 | ||
| Francesc Vidal | Q42430887 | ||
| Ferran Torres | Q43088594 | ||
| P2093 | author name string | Pere Domingo | |
| Maria Saumoy | |||
| Begoña Cordobilla | |||
| Maria Luisa Alvarez | |||
| Jordi Guallar | |||
| Rainel Sánchez de la Rosa | |||
| P2860 | cites work | Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir | Q24321512 |
| Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors | Q24536268 | ||
| Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases | Q28255766 | ||
| Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques | Q28775900 | ||
| Statistical Methods in Medical Research | Q29013788 | ||
| The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. | Q30759685 | ||
| Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study | Q30983924 | ||
| Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine | Q33196165 | ||
| Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients | Q33770032 | ||
| Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. | Q33892331 | ||
| Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults | Q33983070 | ||
| Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. | Q33993644 | ||
| Inducible expression of a dominant negative DNA polymerase-gamma depletes mitochondrial DNA and produces a rho0 phenotype. | Q34184643 | ||
| Effect of tenofovir on didanosine absorption in patients with HIV. | Q34536261 | ||
| Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection | Q34554493 | ||
| Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations | Q34738805 | ||
| Tenofovir-related nephrotoxicity: case report and review of the literature | Q35709802 | ||
| Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir | Q35852636 | ||
| Antiviral drug-induced nephrotoxicity | Q36110651 | ||
| Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment--case report and review of literature | Q36204603 | ||
| Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature | Q36207487 | ||
| Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions | Q36342389 | ||
| Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1. | Q38920848 | ||
| Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. | Q46900196 | ||
| Longitudinal study on mitochondrial effects of didanosine-tenofovir combination | Q46912883 | ||
| 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures | Q46973541 | ||
| Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy | Q46976845 | ||
| Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. | Q50904345 | ||
| Side-effects of ritonavir and its combination with saquinavir with special regard to renal function | Q73324130 | ||
| The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy | Q39340579 | ||
| Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors | Q39391662 | ||
| In vitro antiviral interaction of lopinavir with other protease inhibitors | Q39652270 | ||
| Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. | Q40499963 | ||
| Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs | Q40688656 | ||
| HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells | Q40697876 | ||
| Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. | Q40745355 | ||
| Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system | Q40899458 | ||
| Renal insufficiency induced by ritonavir in HIV-infected patients. | Q42538007 | ||
| Ritonavir and renal failure | Q42551639 | ||
| Renal failure after treatment with ritonavir | Q42554381 | ||
| Dideoxyinosine-associated nephrotoxicity | Q42559031 | ||
| Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion | Q43526884 | ||
| Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs | Q43741891 | ||
| Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine | Q43743810 | ||
| Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. | Q43879910 | ||
| Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study | Q44015302 | ||
| Fanconi syndrome and renal failure induced by tenofovir: a first case report | Q44235015 | ||
| First-line therapy and mitochondrial damage: different nucleosides, different findings | Q44309069 | ||
| Renal lesions in HIV-1-positive patient treated with tenofovir | Q44379167 | ||
| Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus | Q44396659 | ||
| Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine | Q44396661 | ||
| Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome | Q44528008 | ||
| Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected]. | Q44564512 | ||
| Acute tubular necrosis in a patient receiving tenofovir | Q44644295 | ||
| Tenofovir-related nephrotoxicity in HIV-infected patients | Q44827267 | ||
| Renal safety of tenofovir in HIV treatment-experienced patients. | Q44851246 | ||
| Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine? | Q44851404 | ||
| Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults | Q44964458 | ||
| Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial | Q44975155 | ||
| Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? | Q44997975 | ||
| Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure | Q45016447 | ||
| Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate | Q45037788 | ||
| Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine | Q45172095 | ||
| Antiretroviral therapy with tenofovir is associated with mild renal dysfunction | Q45207624 | ||
| Tenofovir-induced acute renal failure in an HIV patient with normal renal function | Q45240250 | ||
| Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice | Q45285932 | ||
| Acute renal failure, Fanconi syndrome and insipidus diabetes in a HIV-infected patient treated with Tenofovir | Q46528481 | ||
| Assessment of renal abnormalities in 107 HIV patients treated with tenofovir | Q46559081 | ||
| Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study | Q46625896 | ||
| High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir | Q46720700 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tenofovir | Q155954 |
| cytotoxicity | Q246181 | ||
| anti-retroviral agent | Q50430310 | ||
| P304 | page(s) | 3824-3832 | |
| P577 | publication date | 2006-08-28 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells | |
| P478 | volume | 50 |
| Q37588728 | A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV. |
| Q34160511 | Aging, human immunodeficiency virus, and bone health |
| Q28474361 | An analysis of enzyme kinetics data for mitochondrial DNA strand termination by nucleoside reverse transcription inhibitors |
| Q37376313 | Antiretroviral compounds and cholesterol efflux from macrophages |
| Q46445488 | Applicability of pharmacogenetic studies in daily clinical practice |
| Q37335637 | BMS-986001, an HIV nucleoside reverse transcriptase inhibitor, does not degrade mitochondrial DNA in long-term primary cultures of cells isolated from human kidney, muscle, and adipose tissue |
| Q43646614 | CD4+ cell count decline despite HIV suppression: a probable didanosine-valganciclovir interaction |
| Q34409132 | Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. |
| Q38040137 | Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation |
| Q38714018 | Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity |
| Q41359427 | Evaluation of biomarkers for in vitro prediction of drug-induced nephrotoxicity: comparison of HK-2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cells |
| Q39118603 | Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. |
| Q28729025 | HIV-1 infection and first line ART induced differential responses in mitochondria from blood lymphocytes and monocytes: the ANRS EP45 "Aging" study |
| Q34737466 | Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients. |
| Q34431200 | Lamivudine/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion |
| Q41920342 | Lopinavir impairs protein synthesis and induces eEF2 phosphorylation via the activation of AMP-activated protein kinase |
| Q89582849 | Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B |
| Q36704152 | Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination |
| Q37798546 | Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA |
| Q36795898 | Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment |
| Q45325519 | Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother-to-child transmission of hepatitis B virus |
| Q34785931 | Quality assessment of human mitochondrial DNA quantification: MITONAUTS, an international multicentre survey |
| Q35981062 | Targeted spontaneous reporting of suspected renal toxicity in patients undergoing highly active anti-retroviral therapy in two public health facilities in Uganda |
| Q26995852 | Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? |
| Q33416391 | Tenofovir renal toxicity targets mitochondria of renal proximal tubules |
| Q33635034 | Tenofovir-associated bone density loss |
| Q61928289 | The Role of Mitochondria in HIV Infection and Its Treatment |
| Q36921993 | The role of transporters in the toxicity of nucleoside and nucleotide analogs |
| Q46445496 | Toxicogenetics of antiretroviral treatment (II): neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs |
Search more.